Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05462574 · ClinicalTrials.gov registry record
Right Ventricle Lipid in Pulmonary Arterial Hypertension (PAH)
A clinical trial of Idiopathic Pulmonary Arterial Hypertension and Heritable Pulmonary Arterial Hypertension, sponsored by Vanderbilt University Medical Center.
- Recruiting
- Registry status
- 75
- Enrollment target
- 1
- Study location
NCT05462574: Recruiting study of Idiopathic Pulmonary Arterial Hypertension and Heritable Pulmonary Arterial Hypertension, sponsored by Vanderbilt University Medical Center.
NCT05462574 is a study of Idiopathic Pulmonary Arterial Hypertension and Heritable Pulmonary Arterial Hypertension that is actively recruiting participants, run by Vanderbilt University Medical Center. The registered enrollment target is 75 participants, below the 690-participant average among 3 other Idiopathic Pulmonary Arterial Hypertension trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05462574, a study of Idiopathic Pulmonary Arterial Hypertension and Heritable Pulmonary Arterial Hypertension, is actively recruiting participants, sponsored by Vanderbilt University Medical Center.
- RECRUITING
- Registry status
- 75 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators propose to study the relationship between right ventricle (RV) steatosis and RV function, exercise capacity, and outcomes in humans with pulmonary arterial hypertension (PAH) and to identify potential drivers of lipid accumulation.
Primary Outcome
Change in RV ejection fraction will be measured by cardiac MRI.
Conditions Studied
Interventions
- OTHER No Intervention
Study Locations (1)
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2023-01-17 |
| Est. Completion | 2027-09-30 |
What NCT05462574 shows while recruiting
NCT05462574 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 690-participant average among 3 other Idiopathic Pulmonary Arterial Hypertension trials with a reported enrollment target (89% lower).
The record links to 3 conditions, with Idiopathic Pulmonary Arterial Hypertension appearing as the primary indexed condition, and to 1 intervention - of which No Intervention is the first listed.
NCT05462574 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT05462574 about?
NCT05462574 is a clinical study titled "Right Ventricle Lipid in Pulmonary Arterial Hypertension (PAH)". The investigators propose to study the relationship between right ventricle (RV) steatosis and RV function, exercise capacity, and outcomes in humans with pulmonary arterial hypertension (PAH) and to identify potential drivers of lipid accumulation.
What is the current status of trial NCT05462574?
This trial is currently recruiting. The enrollment target is 75 participants. The study started on 2023-01-17. Estimated completion is 2027-09-30.
What conditions does trial NCT05462574 study?
This clinical trial studies the following conditions: Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension Associated With Connective Tissue Disease.
What interventions are being tested in trial NCT05462574?
The interventions under investigation include: No Intervention (OTHER).
Who is sponsoring clinical trial NCT05462574?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05462574 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Idiopathic Pulmonary Arterial Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Hormonal, Metabolic, and Signaling Interactions in PAH
RECRUITING
-
129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH)
RECRUITING · Phase 2
-
Risk and Resilience in Pulmonary Arterial Hypertension and Genetically Susceptible Individuals
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02232191 · 75 participants · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI